AllDocs -> cancers

Multiple myeloma A Concise Review of the Disease and Treatment Options Prepared by Brian G. M. Durie, MD Page 2 Contents p 1 Introduction p 2 What is Myeloma ? p 6 History p 11 Epidemiology and Pathophysiology p 14 Clinical Symptoms p 15 Staging and Prognostic Factors p 18 Definition of Clinical Response p 19 Treatment p 36 References Mission Statement Dedicated to improving the quality of life of Myeloma patients while working towards prevention and a cure. This is one of a range of publications covering many aspects of living with Multiple Myeloma . Please contact the IMF (UK) for more details. This is an overview of the history of myeloma , a discussion of pathophysiology, clinical features plus treatment options. It is written for physicians ...

Program Faculty Rafat Abonour, MD Associate Professor, Section of Hematology/Oncology Department of Medicine Department of Pathology and Laboratory Medicine Indiana University School of Medicine Indianapolis, Indiana Rafat Abonour, MD, is Associate Professor of the Section of Hematology/Oncology in the Department of Medicine as well as in the Department of Pathology and Laboratory Medicine at Indiana University School of Medicine in Indianapolis. Dr. Abonour received his medical degree from the University of Damascas in Syria. His training also included a postdoctoral fellowship in Immunology at the University of Wisconsin, where he also completed residencies in Internal Medicine. Certified by the American Board of Internal Medicine, Dr. Abonour is a member of the American College of Physicians, American Society of Hematology, American Society of Clinical Oncology, and ...

Multiple Myeloma Emerging Therapy Rafat Abonour Indiana University School of Medicine Page 2 Multiple Myeloma The First Recognized Case • A 39 year old woman developed severe back pain in 1840. • Two years later she developed severe pain while her husband was carrying her from the fireplace to the bed. • A bitter infusion for her poor appetite was given, but the patient refused it. • Two years later she was admitted to St. Thomas Hospital and was allowed wine, mutton chop, and a pint of porter daily. Page 3 BJH, 2000, 111, 1035-44 Multiple Myeloma The First Recognized case Sarah Newberry, 1844. Fractures of femurs and right humerus Page 4 Multiple Myeloma The First Recognized case • Despite the infusion of orange peel and ...

MEDICAL PROGRESS Volume 336 Number 23 1657 Review Article Medical Progress M ULTIPLE M YELOMA R ÉGIS B ATAILLE , M.D., P H .D., AND J EAN -L UC H AROUSSEAU , M.D. From the Laboratory of Hematology, Institute of Biology (R.B.), and the Department of Clinical Oncology and Hematology (J.-L.H.), Univer- sity Hospital, Nantes, France. Address reprint requests to Dr. Bataille at the Laboratoire d’Hématologie, Institut de Biologie, 9, Quai Moncousu, 44035 Nantes CEDEX 01, France. ©1997, Massachusetts Medical Society. ULTIPLE myeloma is a disorder in which malignant plasma cells accumulate in the bone marrow and produce an immuno- globulin, usually monoclonal IgG or IgA. Common complications of overt multiple myeloma ...

Turk J Med Sci 2006; 36 (4): 247-250 © TÜB‹TAK E-mail: medsci@tubitak.gov.tr 247 CASE REPORT Arterial Thrombosis in Refractory Multiple Myeloma Patient Treated with Thalidomide and Dexamethasone: A Case Report Abstract: A 48-year-old man with relapsing multiple myeloma (MM) presented with serum monoclonal protein (IgG ? ) of 5.93 g/dl. He was initially treated with four cycles of VAD (vincristine, adriamycin and dexamethasone) but due to deterioration of his renal functions with disease relapse, he was placed on hemodialysis. A combined treatment with thalidomide at a daily dose of 200 mg and 4-d cycles of dexamethasone was started for relapsing MM. Thalidomide dose was increased to 400 mg after two weeks. In the second month of his treatment, the patient presented with progressive drowsiness without other symptoms. His cranial MR was suggestive of arterial thrombosis. ...

CANCER INCIDENCE IN THE SACRAMENTO REGION,1988-2001 46 Male Incidence Male Mortality Female Incidence Female Mortality 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 Figure 19: Age-Adjusted Incidence (AAIR) and Mortality (AAMR) Rates,byYear,Sacramento Region,California,1988-2001: Multiple Myeloma 0 1 2 3 4 5 6 7 8 9 10 AAIR and AAMR (C ases/Dea ths per 100,000) MYELOMA Table 21: Number of New Cancer Cases, Deaths, and Age-Adjusted Incidence and Mortality Rates, by Race/Ethnicity, County, and Sex, Sacramento Region, California, 1997-2001: Myeloma Total Male Female Cases AAIR Deaths AAMR Cases AAIR Deaths AAMR Cases AAIR Deaths AAMR All Races Combined 668 4.9 503 ...

New and Emerging Therapies for Multiple Myeloma By Dr. Heather Leitch, MD, PhD, FRCPC Hematologist, St. Paul’s Hospital, Vancouver, BC Clinical Associate Professor, University of British Columbia Myeloma is a cancer of plasma cells, cells of the immune system which produce antibodies or immunoglobulins. Myeloma is identified by abnormal levels of certain immunoglobulins or paraproteins (M-proteins) in the blood or urine. Over the past decade there has been steady progress in improving treatments and preventing complications of the disease. People with myeloma are now living longer than ever before. As new and future therapies are developed, are tested, and become available, it is anticipated the lives of myeloma patients will be lengthened and their quality of life improved. First-line and Supportive Therapies Currently, the only treatment that can potentially cure myeloma is stem ...

300 Clinical Advances in Hematology & Oncology Volume 4, Issue 4 April 2006 Myeloma and Bone Disease: “The Dangerous Tango” Joshua Epstein, DSc, and Ronald Walker, MD Dr. Epstein is Professor of Medicine in the Myeloma Institute for Research and Therapy at the University of Arkansas Medical Sciences College of Medicine in Little Rock, where Dr. Walker is Assistant Professor, Diagnostic Radiology, in the Department of Radiology. Address correspondence to: Joshua Epstein, DSc, Myeloma Institute for Research and Therapy, University of Arkansas Medical Sciences College of Medicine, 4301 W. Markham #776, Little Rock, AR 72205; Tel: 501-686-8250; E-mail: epsteinjoshua@uams.edu. Abstract: Osteolytic bone disease is the most debilitating mani- festation of myeloma . However, myeloma -induced effects on the bone-active cells in the bone marrow ...

Dr. Bart Barlogie, director of the Myeloma Institute for Research and Therapy and a professor of medicine and pathology at the University of Arkansas for Medical Sci- ences’ College of Medicine, was named the inaugural recipient of the J. Thomas May Chair in Oncology at a ceremony held May 24 at UAMS. The endowed chair was the result of a gift of more than $1 million from Little Rock’s William E. and Margaret Clark to UAMS in honor of May, chairman and chief executive officer of Simmons First National Corporation and Simmons First National Bank. May has an extensive background in civic and community affairs, including ser- vice on the UAMS Department of Psychiatry capital campaign steering committee. “This gift from the Clarks is an investment in the future,” May said. “I am honored to have my name permanently associated with a world-class organization ...

Invasive Cancer Incidence by Race Illinois, 1986-2003 Myeloma , Both Sexes All Races Whites Years Count Rate SE LCI UCI Count Rate SE LCI UCI 1986-2003 11,216 5.5 0.1 5.4 5.6 8,591 4.8 0.1 4.7 4.9 1986 429 4.1 0.2 3.7 4.5 340 3.6 0.2 3.2 4.0 1987 464 4.4 0.2 4.0 4.8 361 3.8 0.2 3.4 4.2 1988 468 4.4 0.2 4.0 4.8 379 4.0 0.2 3.6 4.4 1989 503 4.7 0.2 4.3 5.1 410 4.3 0.2 3.9 4.8 1990 511 4.7 0.2 4.3 5.1 391 4.0 0.2 3.6 4.5 1991 549 5.0 0.2 ...

Cancer Mortality by Race, Illinois, 1986-2003 Myeloma , Both Sexes All Races Whites Years Count Rate SE LCI UCI Count Rate SE LCI UCI 1986-2003 8,012 3.9 0.0 3.8 4.0 6,277 3.5 0.0 3.4 3.6 1986 407 3.9 0.2 3.5 4.3 324 3.5 0.2 3.1 3.9 1987 385 3.6 0.2 3.3 4.0 298 3.1 0.2 2.8 3.5 1988 381 3.6 0.2 3.2 3.9 316 3.3 0.2 3.0 3.7 1989 422 3.9 0.2 3.5 4.3 329 3.4 0.2 3.1 3.8 1990 384 3.6 0.2 3.2 4.0 309 3.2 0.2 2.9 3.6 1991 415 3.8 0.2 ...

Multiple Myeloma Evaluation of five staging systems in 470 patients with multiple myeloma We evaluated the prognostic significance of five staging systems in 470 consecutive, previously untreated patients with multiple myeloma diagnosed between 1989 and 2006. The five staging systems were those proposed by Durie and Salmon, Bataille et al., the South West Oncology Group, Weber et al. and the International Staging System. This last proved to be superior to the others. Haematologica 2006; 91:1149-1150 ( http://www.haematologica.org/journal/2006/08/1149.html) The wide range in survival rates in multiple myeloma (MM) establishes the need for a staging system (SS) with prognostic reliability. Since 1975, the Durie-Salmon SS (DS SS) has been a widely accepted classification of MM patients, despite its lack of reproducibility, problematic ...

Mayo Clin Proc. • August 2006;81(8):1047-1053 • www.mayoclinicproceedings.com 1047 MAYO CLINIC CONSENSUS STATEMENT FOR BISPHOSPHONATES IN MM SPECIAL ARTICLE From the Division of Hematology (M.Q.L., A.D., M.A.G., P.R.G., K.L.G., S.R.H., S.K., J.A.L., S.V.R., S.J.R., T.E.W., S.R.Z., D.D., R.A.K.), Department of Dental Specialties (A.B.C.), and Division of Oral Diagnosis and Oral and Maxillofacial Surgery (D.K., E.E.K., C.F.V.), Mayo Clinic College of Medicine, Rochester, Minn; Division of Hematology/Oncology, Mayo Clinic College of Medicine, Scottsdale, Ariz (P.L.B., R.F., C.B.R., A.K.S.), Division of Hematology/Oncol- ogy, Mayo Clinic College of Medicine, Jacksonville, Fla (V.R.), and Division of Medical Oncology, Mayo Health System, Mankato, Minn (R.J.D.). Dr Dalton owns stock in Genentech, Inc. Address reprint requests and correspondence to Martha Q. Lacy, MD, Division of Hematology, Mayo Clinic ...

O n January 13th the Tomioka (Fuku- shima Prefecture) office of the Labor Standards Office accepted the claim of Mitsuaki Nagao that his multiple myeloma (a form of bone marrow cancer) was contracted as a result of his work at nuclear reactors. The decision relates to work that Mr Nagao (78) did for a construction company on the piping of nuclear reactors and also as a superviser of such work. Multiple myeloma is not listed as a recognized condition for workers' compensa- tion related to work at nuclear reactors. The five cases recognized previously for work at nuclear reactors were all forms of leukemia. This is the first case of a condition other than leukemia being recognized. It is a very encour- aging decision, which holds out hope that other conditions may be recognized in future. In multiple myeloma the bones throughout the whole body are weakened ...

ELIGIBILITY FORM Pamidronate for Plasma Cell Myeloma (This form should be completed before the first dose is dispensed) 1. PATIENT SURNAME 2. GIVEN NAME _ 3. DATE OF BIRTH __ __ • __ __ • __ __ Day Month Year 4. HEALTH INSURANCE NUMBER __ 5. CENTRE (Circle correct response) 1 Hamilton 2 Kingston 3 London 4 Ottawa Civic 5 Ottawa General 6 Sudbury 7 Thunder Bay 8 Toronto-Sunnybrook 9 Windsor 10 PMH 11 Other (specify below) Other : __ 6. ATTENDING PHYSICIAN __ If not a Cancer Centre physician, please indicate your phone number __ 7. ELIGIBILITY a. The patient has plasma cell myeloma Yes b. The patient has evidence of bony lesions (lytic lesions or osteopenia) Yes OR The Patient has ...

The MMRF was invited to speak at the 2006 Milken Institute Conference, held April 24-26 in Los Angeles, CA, to discuss the importance of philanthropy in advancing medical research and in building innovative research models like the Multiple Myeloma Research Consortium (MMRC). MMRF and MMRC Chief Executive Officer, Kathy Giusti, sat on the panel, The New Philanthropists and the Future of Medical Research Funding , alongside Lance Armstrong, tour de France champion and cancer survivor, Eli Broad, Founder of The Broad Foundation, Michael Milken, Chairman of the Milken Institute, and Carl Schramm, President and CEO of the Ewing Marion Kauffman Foundation. “It was a true honor to serve as a panelist at the Milken Conference,” said Kathy Giusti. “This important event provided a unique opportunity to work with global leaders to develop innovative strategies to advance medical research and accelerate the development of ...

1 Highlights from Novel Therapeutic Avenues in Myeloma : Changing the Paradigm (Clinical Science Symposium) Rafael Fonseca, MD Mayo Clinic Scottsdale, Arizona Newly Diagnosed Multiple Myeloma Page 2 2 PN=Peripheral Neuropathy Anderson K, et al. ASCO 2006, Abstract 7504. Single-Agent Bortezomib in Newly Diagnosed MM Study Objectives • Primary – Overall Response Rate • Secondary – Time-to-progression – Safety – Incidence and severity of PN – Impact of dose modifications on PN – Effect of pharmacologic interventions on PN Dispenzieri A, et al. Blood . 2005;106. Abstract 2546. Jagannath S, et al. Blood . 2005;106. Abstract 783. Single-Agent Bortezomib for Patients With Newly Diagnosed MM 41% 16/40 Bortezomib ...

1 Highlights From the Oral Abstract Session on Multiple Myeloma Sagar Lonial, MD Winship Cancer Institute Emory University Atlanta, Georgia Newly Diagnosed Multiple Myeloma Page 2 2 Bladé Criteria Rajkumar SV, et al. ASCO 2006, Abstract 7517. Thal/Dex as Initial Therapy for Newly Diagnosed MM Patients Response Rate (%) 4.7 43.8 1.3 34 0 20 40 60 Thal/Dex Dex PR (>50%) CR (IF-) * p <.01 48.5%* 35.3%* Response Rate Rajkumar SV, et al. ASCO 2006, Abstract 7517. Thalidomide/dexamethasone Median TTP: not reached Dexamethasone alone Median TTP: 8.1 months 0.2 0.4 0.6 0.8 1.0 0 6 12 18 ...

Genmab A/S Toldbodgade 33 1253 Copenhagen K Denmark Tel + 45 7020 2728 Fax + 45 7020 2729 CVR no. 2102 3884 Genmab A/S 1/2 Stock Exchange Release no. 22/2005 Contact: Helle Husted Director, Investor Relations T: +45 33 44 77 30 M: +45 25 27 47 13 E: hth@genmab.com GENMAB ANNOUNCES MULTIPLE MYELOMA ANTIBODY PROGRAM Copenhagen, Denmark; May 12, 2005 – Genmab A/S (CSE: GEN) announced today its new HuMax ® -CD38 program for the treatment of multiple myeloma . HuMax-CD38 is a human IgG1,? antibody selected from a large panel of antibodies based on its ability to bind and to kill multiple myeloma tumor cells. The HuMax-CD38 antibody targets the CD38 molecule which is very highly expressed on the surface of multiple myeloma cells. In preclinical studies, HuMax-CD38 was effective in killing primary ...

Mayo Clin Proc. • July 2006;81(7):877-879 • www.mayoclinicproceedings.com 877 EDITORIAL Multiple Myeloma : New Options, New Challenges EDITORIAL Address correspondence to Martha Q. Lacy, MD, Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905 (e- mail: lacy.martha@mayo.edu). © 2006 Mayo Foundation for Medical Education and Research See also page 889 T he development of novel agents for the treatment of multiple myeloma (MM) has resulted in a plethora of new combination regimens. The high response rates ob- served with these combination regimens have raised ques- tions about whether autologous stem cell transplantation (ASCT) should still be offered to patients as initial therapy. In this issue of Mayo Clinic Proceedings , Dr Hussein and colleagues 1 report results of their trial combining ...

Mayo Clin Proc. • July 2006;81(7):869 • www.mayoclinicproceedings.com 869 RUNNING HEAD MEDICAL IMAGES Pseudothrombocytopenia Associated With Multiple Myeloma B RYAN W. R EED , DO,* AND R ONALD S. G O , MD† *Department of Internal Medicine and †Section of Hematology, Gundersen Lutheran Medical Center, La Crosse, Wis A 90-year-old woman presented with progressive fa- tigue of 3 months’ duration. On physical examina- tion, she was pale and jaundiced. Initial laboratory tests revealed the following abnormal findings: hemoglobin level, 10 g/dL; reticulocyte count, 115 × 10 9 /L; platelet count, 3 × 10 9 /L; total bilirubin (indirect), 3.7 mg/dL; and direct antiglobulin test, positive for IgG. A peripheral blood smear showed massive platelet ...

1 INTERNATIONAL MYELOMA FOUNDATION 2007 Brian D. Novis Research Award Junior Grant Application JUNIOR GRANT APPLICATION INTERNATIONAL MYELOMA FOUNDATION 2007 BRIAN D. NOVIS RESEARCH AWARD Provided by donations from private individuals The International Myeloma Foundation funds several research grants including the Brian D. Novis Research Award. These grants are provided through donations from private individuals, and are presented annually by the International Myeloma Foundation. These awards go to doctors/researchers doing work in the field of multiple myeloma . This year's awards will be in the amount of $40,000. The Brian D. Novis Award honors the IMF’s founder Brian Novis, who died of multiple myeloma in July of 1992. The International Myeloma Foundation is a non-profit organization whose mission is to improve the quality of life for myeloma patients while working ...

INTERNATIONAL MYELOMA FOUNDATION 2007 Brian D. Novis Research Award Senior Grant Application SENIOR GRANT APPLICATION INTERNATIONAL MYELOMA FOUNDATION 2007 BRIAN D. NOVIS RESEARCH AWARD Provided by donations from private individuals The International Myeloma Foundation funds several research grants including the Brian D. Novis Research Award. These grants are provided through donations from private individuals, and are presented annually by the International Myeloma Foundation. These awards go to doctors/researchers doing work in the field of multiple myeloma . This year’s awards will be in the amount of $80,000. The Brian D. Novis Award honors the IMF’s founder Brian Novis, who died of multiple myeloma in July of 1992. The International Myeloma Foundation is a non-profit organization whose mission is to improve the quality of life for myeloma patients while working toward ...

Myeloma updated 1st edition 1998 Robert A. Kyle MANUAL Multiples Myelom © 2002 by Tumorzentrum München und W. Zuckschwerdt Verlag München VII the size of the M-protein and the number of bone marrow plasma cells are helpful in diagnosis, we find that the plasma cell labelling index and the presence of circulating peripheral blood plasma cells are also useful.Virtually all patients with an elevated plasma cell labelling index or circulating plasma cells in the peripheral blood have active multiple myeloma . The physician must realise that the presence of a normal plasma cell label- ling index or absence of circulating plasma cells does not exclude the possibility of active multiple myeloma . If the patient is younger than 65 or 70 years, the physician should discuss the possibility of auto- logous peripheral blood stem cell transplanta- tion. Ideally, ...

As a result of its renowned success, Bartl and colleagues have updated and extended their Manual on Multiple Myeloma with recommen- dations for diagnostics, treatment and support- ive care. Multiple myeloma represents the most ad- vanced and clinically devastating form of plas- ma cell dyscrasias.The past five years have seen major advances in the biology and genetics of this prototypic clonal B cell tumor with a ter- minally differentiated plasmacytic phenotype. Etiology remains elusive, although a number of environmental factors including HHV-8. Patho- genetically , the disease is thought to develop in a B-cell, which has traversed the germinal cen- ter of lymph nodes, with a plasmablast or B-memory cell likely to represent the site of malignant transformation, as suggested by extensive hypermutations of the CDR regions of the immunoglobulin gene.In contrast to most ...

10th Anniversary Multiple Myeloma Research Foundation “Friends for Life” Fall Gala Saturday, October 28, 2006 Hyatt Regency – Greenwich, CT __Gala Benefactor $25,000 Name on all printed materials and signage, full-page ad in program book, verbal recognition during formal program, priority seating for a table of 10 (top seating with celebrity guests, MMRF Scientific Advisors and/or Board of Directors) Gala Sponsor $15,000 Name on all printed materials and signage, full-page ad in program book, verbal recognition during formal program, priority seating for a table of 10 (select seating with celebrity guests, MMRF Scientific Advisors and/or Board of Directors) Gala Patron $10,000 Name on all printed materials, half-page ad in program book, one table of 10 seats in prime location of ballroom (after Sponsors) Gala Partner $5,000 ...

Center for Environmental Health Studies (617) 482-9485 44 Farnsworth Street, Boston, MA 02210 http://www.jsi.com Multiple Myeloma (MM) and Exposure to Ionizing Radiation 1 Multiple Myeloma (MM) and Exposure to Ionizing Radiation Summary : Studies conducted at the Los Alamos National Laboratory and other nuclear facilities, as well as those exposed to radiation from the atomic bomb suggest an increased likelihood of developing multiple myeloma for those who have been exposed to ionizing radiation. These findings are consistent with the determination of the National Research Council’s BEIR V committee that multiple myeloma has been associated with exposure to ionizing radiation. Multiple myeloma is a “specified” cancer under the EEOICPA. Historically, multiple myeloma incidence and mortality in Los Alamos County fall in the middle of New Mexico counties while ...

September, 2003 This Report on Leukemia, Lymphoma and Multiple Myeloma Contains: • Cancers by Age Group and Gender • Incidence Rates by Gender and Race • Survival Probabilities • Risk Factors • Sources of Additional Information The Ohio Cancer Incidence Surveillance System (OCISS) Blood-related cancers originate in the bone marrow (Leukemia and Multiple Myeloma ) or lymphatic tissue (Non-Hodgkin’s and Hodgkin’s Lymphomas). These cancers involve the uncontrolled growth of cells with similar functions and origins and result from an acquired genetic injury to DNA of a single cell, which becomes malignant (cancerous) and multiplies continuously. The accumulation of malignant cells interferes with the body’s production of healthy blood cells and ability to protect itself against infections. ...